ClpP粘膜免疫预防小鼠发生肺炎链球菌性肺炎和败血症

Mucosal immunization with ClpP could protect mice from pneumococcal pneumonia and sepsis

目的:肺炎链球菌毒力蛋白ClpP鼻腔粘膜免疫BALB/c小鼠,探讨其作为肺炎链球菌候选蛋白疫苗的价值。方法:利用制备的ClpP多克隆抗体,分析ClpP在肺炎链球菌表面表达情况;ClpP蛋白粘膜免疫小鼠,TIGR4型肺炎链球菌分别经腹腔和鼻腔攻击,分析肺炎链球菌小鼠肺内定植情况并监测小鼠生存时间。结果:流式细胞技术证实了TIGR4肺炎链球菌表面表达ClpP毒力蛋白,粘膜免疫ClpP可以特异产生系统性和粘膜性的ClpP抗体,并可减少TIGR4肺炎链球菌在小鼠肺内的定植,延长小鼠生存时间。结论:ClpP粘膜免疫可预防小鼠发生肺炎链球菌性肺炎和败血症,进一步证实ClpP蛋白可作为肺炎链球菌的候选蛋白疫苗。

Objective：To investigate whether mucosal immunization with purified ClpP could elicit protective efficacy against pneumococcal pneumonia and sepsis in mice. Methods： BALB/c mice were intraperitoneally immunized with recombinant ClpP protein and then the hyperimmune serum antibodies was obtained. Flow cytometry was used to determine the abilities of the antibodies to bind with the surface of live S. pneumoniae cells. And we examined the capacity of mucosal immunization with recombinant ClpP to protect mice from pneumococcal pneumonia and sepsis challenged with TIGR4 streptococci. Results： Surface localization of ClpP was confirmed using flow cytometry analysis. Mucosal immtmization with ClpP antigen induced both systemic and mucosal antibodies, and this regimen could reduce lung colonization in a pneumococcal pneumonia model and also protect mice from death in an intraperitoneal-sepsis model. Conclusion： Mucosal immunization with purified ClpP could elicit protective efficacy against pneumococcal pneumonia and sepsis in BALB/c mice as a promising candidate for vaccine development.